ResMed (ASX:RMD) Cash Flow for Dividends: A$-508 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RMD ResMed Inc ASX:RMD
98 GF Score
Price A$28.61
GF Value A$40.60
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Cash Flow for Dividends?

ResMed ASX:RMD +0.14% 98 Cash Flow for Dividends is A$-508 Mil as of Mar. 2026. GuruFocus rates ASX:RMD with a GF Score™ of 98/100 and a GF Value™ of A$40.60 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ResMed's cash flow for dividends for the three months ended in Mar. 2026 was A$-124 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was A$-508 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

ResMed's quarterly payment of dividends declined from Sep. 2025 (A$-133 Mil) to Dec. 2025 (A$-132 Mil) and declined from Dec. 2025 (A$-132 Mil) to Mar. 2026 (A$-124 Mil).

ResMed's annual payment of dividends increased from Jun. 2023 (A$-385 Mil) to Jun. 2024 (A$-425 Mil) and increased from Jun. 2024 (A$-425 Mil) to Jun. 2025 (A$-478 Mil).

ResMed Cash Flow for Dividends Related Terms

ResMed Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for ResMed's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Cash Flow for Dividends Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -296.54 -349.12 -384.83 -425.17 -477.51

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -123.32 -119.18 -133.03 -131.81 -124.31
ASX:RMD
98GF Score
ResMed Inc ASX:RMD
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-508 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of A$-508 Mil mean?
ResMed (ASX:RMD) has a Cash Flow for Dividends of A$-508 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for ResMed and its competitors.
Is ResMed's Cash Flow for Dividends too high?
ResMed's current Cash Flow for Dividends is A$-508 Mil. Overall, ResMed has a GF Score™ of 98/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Cash Flow for Dividends compare to MDLN and WST?
ResMed's Cash Flow for Dividends of A$-508 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Medical Devices & Instruments company?
A good Cash Flow for Dividends depends on the Medical Devices & Instruments industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for ResMed and its competitors. ResMed's current Cash Flow for Dividends is A$-508 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is A$40.60, compared to a current price of A$28.61 — trading 29.5% below its estimated fair value. The current Cash Flow for Dividends is A$-508 Mil. ResMed's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Cash Flow for Dividends is A$-508 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (ASX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of A$28.61 is trading 29.5% below its estimated GF Value™ of A$40.60. GuruFocus considers ResMed to be Significantly Undervalued.

Key valuation signals for ASX:RMD:

  • Cash Flow for Dividends: A$-508 Mil
  • GF Value™: A$40.60 vs. price of A$28.61 (29.5% below fair value)
  • GF Score™: 98/100 with 1 warning sign

No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
98GF Score

Get the complete analysis for ASX:RMD

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$28.61
Price
A$40.60
GF Value